Our portfolio demonstrates our expertise in Clinical Development, Operations, Business Development, Medical Affairs, and Biometrics.
We are pleased to showcase just some of our deep expertise and significant achievements across the Medical, Biometrics and Operational deliverables of Drug Development and Medical Affairs. Our extensive portfolio not only highlights our broad capabilities but also underscores the pivotal contributions of Dr. Bozón, whose strategic insights and innovative approaches have driven the success of numerous high-stakes projects.
By exploring our detailed client stories, you will see firsthand the transformative impact our tailored approaches have had on the biotech and pharmaceutical industries, solidifying our reputation as leaders in biopharma consulting.
We are proud to feature the personal contributions of Dr. Bozón, whose innovative solutions and strategic guidance have been instrumental in driving project success in support of corporate strategy advancement and business development success. Explore our client stories to see how our tailored approaches have made a significant impact in the biotech and pharmaceutical industries.
- Ribon Therapeutics
Senior Vice-President at Ribon Therapeutics (2020-2023): As Head of Clinical Development, Dr. Bozón led pivotal drug development initiatives globally in different therapeutic areas, contributing to Ribon’s growth and innovation in the biotech landscape. - Fosun Pharma
Chief Medical Officer, Ex-China at Fosun Pharma (2018-2020): She spearheaded medical and clinical strategies outside of China, filed multiple INDs, held FDA interactions to leverage diverse clinical data in support of US IND submissions, enhancing Fosun Pharma’s global presence and impact. - EMD Serono
Senior Medical Director, US Medical Affairs at EMD Serono (2017-2018): In this role, she played a key part in shaping the medical affairs strategy in immuno-oncology in the United States, further establishing EMD Serono’s commitment to medical excellence. - Array Biopharma
Senior Medical Director at Array Biopharma (2015-2017): Dr. Bozón was instrumental in advancing Array Biopharma’s clinical development portfolio, including execution in Phase 3 pivotal trials and NDA submission, demonstrating her expertise in leading complex clinical programs. - Takeda
Medical Director at Takeda (2008-2015): Her tenure at Takeda was marked by significant contributions to early and late-stage clinical programs and medical affairs initiatives, showcasing her ability to drive cross functional medical strategy and execution. Dr Bozón led the internal Melanoma multi-disciplinary group and multiple advisory boards and drove the execution of clinical assets to advance their development. - Pfizer
Senior Medical Director, Global Medical Affairs and Clinical Development at Pfizer Inc. (1997-2008): Dr. Bozón commenced her career at Pfizer, where she laid the foundation for her expertise in drug development and global medical strategy. At Pfizer, she was one of the clinicians that led the Phase 1 and Phase 2 studies of tremelimumab, an anti-CTLA4 monoclonal antibody, was part of the early immuno-oncology team that helped transform treatment options and outcome for patients with melanoma and cancer. Dr. Bozón was also the recipient of the Pfizer Achievement Award for the successful defense before the FDA Oncology Advisory Committee (ODAC) that led to the approval of Fragmin (dalteparin sodium) to treat extended symptomatic VTE in patients with cancer, a supplemental indication that was launched globally.